IMAGABALIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H19NO2
Molecular Weight	173.2527
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC[C@@H](C)C[C@H](N)CC(O)=O

InChI

InChIKey=JXEHXYFSIOYTAH-SFYZADRCSA-N

InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00738738 | https://www.ncbi.nlm.nih.gov/pubmed/21664606

Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.

Originator

Approval Year

PubMed

Title	Date	PubMed
Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology.	2011 Jul 15	21664606

Patents

Sample Use Guides

In Vivo Use Guide

Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months

Route of Administration: Oral

Name

Type

Language

IMAGABALIN

Official Name

English

OCTANOIC ACID, 3-AMINO-5-METHYL-, (3S,5R)-

Common Name

English

PD-0332334

Code

English

PD0332334

Code

English

(3S,5R)-3-Amino-5-methyl-octanoic acid

Systematic Name

English

imagabalin [INN]

Common Name

English

IMAGABALIN [USAN]

Common Name

English

PF-00195889

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C28197